Académique Documents
Professionnel Documents
Culture Documents
Insulin resistance is among the most prevalent endocrine derangements in the world, and it is closely associated
with major diseases of global reach including diabetes mellitus, atherosclerosis, nonalcoholic fatty liver disease,
and ovulatory dysfunction. It is most commonly found in those with obesity but may also occur in an unusually
severe form in rare patients with monogenic defects. Such patients may loosely be grouped into those with
primary disorders of insulin signaling and those with defects in adipose tissue development or function (lipodystrophy). The severe insulin resistance of both subgroups puts patients at risk of accelerated complications and
poses severe challenges in clinical management. However, the clinical disorders produced by different genetic
defects are often biochemically and clinically distinct and are associated with distinct risks of complications. This
means that optimal management of affected patients should take into account the specific natural history of
each condition. In clinical practice, they are often underdiagnosed, however, with low rates of identification of
the underlying genetic defect, a problem compounded by confusing and overlapping nomenclature and classification. We now review recent developments in understanding of genetic forms of severe insulin resistance
and/or lipodystrophy and suggest a revised classification based on growing knowledge of the underlying
pathophysiology. (Endocrine Reviews 32: 498 514, 2011)
I. Introduction
II. Definition and Prevalence of Severe IR
III. Generic Clinical Features of Severe IR
A. Abnormal glucose homeostasis
B. Ovarian dysfunction
C. Acanthosis nigricans
IV. Clinical Features Limited to Some Severe IR Subtypes
A. Dyslipidemia and hepatic steatosis
B. Abnormal adipose development or topography
C. Growth disorders
V. Sexual Dimorphism in Severe IR
VI. Biochemical Subphenotyping of Severe IR
VII. Monogenic IR Classification/Nomenclature
VIII. The INSR Spectrum
IX. Downstream Insulin Signaling Defects
X. Disorders of Adipose Tissue Development/Function
(Lipodystrophies)
XI. Digenic IR
XII. Complex Syndromes
XIII. Therapy
A. Dietary and lifestyle modification
B. Insulin sensitization and replacement
C. Adipose tissue offloading
XIV. Summary
nsulin resistance (IR), or more precisely the reduced responsiveness of the body to the glucose-lowering activity of insulin, is closely associated with some of the most
prevalent chronic clinical disorders, namely type 2 diabetes, atherosclerosis, polycystic ovarian syndrome, and hepatic steatosis. The population-wide toll of morbidity and
mortality attributable to IR is large and growing, in particular due to the consequences of coronary artery disease
(1), type 2 diabetes (2), polycystic ovary syndrome (3), and
fatty liver disease, and indeed IR is a cardinal feature of the
metabolic syndrome itself (4).
Although IR is a trait with significant heritability (5 8),
it is usually only clinically expressed in the context of obesity, especially where this has a predominantly centripetal
distribution. In a small number of patients, however, IR of
an unusually severe degree develops without obesity, or in
association with generalized or regional lack of adipose
tissue. Many such patients harbor pathogenic single gene
498
edrv.endojournals.org
I. Introduction
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
edrv.endojournals.org
499
Clinical awareness of IR is greatest among those caring for patients with established diabetes mellitus, where
it is recognized most commonly by a requirement for large
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
500
Semple et al.
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
edrv.endojournals.org
501
whether due to a primary signaling defect or due to lipodystrophy. Some features of severe IR syndromes, in contrast, are seen in only some subtypes.
A. Dyslipidemia and hepatic steatosis
Fig. 3. Acanthosis nigricans (AN) in severe IR. A, Severe AN on the neck in a prepubertal patient with autosomal dominant IR of unknown cause.
B, AN associated with exuberant axillary acrochordons in a 50-yr-old male with severe IR of unknown cause. CF, AN in abdominal skin flexures of
a 15-yr-old boy with severe IR due to a heterozygous INSR mutation (C), on the foot of a patient with congenital generalized lipodystrophy and
severe IR due to homozygous AGPAT2 mutations (D), on the knuckles in a prepubertal patient with severe IR of unknown cause (E), and on the
neck of a prepubertal girl with RMS due to a homozygous INSR mutation (F). G, Histological appearances from a nuchal skin biopsy showing
characteristic papillomatosis (solid arrows), hyperkeratosis, and some acanthosis (open arrow). [Histological image courtesy of Dr. Ed Rytina.]
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
502
Semple et al.
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
in future, enhancing clinical ability to discern any organselective forms of severe IR.
This concept of IR subphenotypes has been exploited
diagnostically by using it to subclassify IR and target genetic screening, greatly enhancing efficiency of molecular
diagnosis of INSR defects (68, 70). Thus, in the context of
severe IR, we have found that adiponectin levels above 7
mg/liter have a 97% positive predictive value for insulin
receptoropathy (70), although the precise cutoff is assayspecific. SHBG and IGFBP1 levels have lesser, although
still significant, utility.
edrv.endojournals.org
503
Affecting only some intracellular arms of the insulin signaling pathway, or variable among tissues.
In addition to frank obesity or lipodystrophy, there is a less well-defined group of disorders having clinical and biochemical evidence of adipose tissue failure and
severe dyslipidemia despite grossly normal whole body adipose tissue mass.
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
504
Semple et al.
In some patients with DS or RMS, loss of INSR expression from one allele has been identified and has been
inferred to be due to a mutation in a regulatory sequence
such as the promoter (84). However, four patients with
severe IR and extremely low expression of both alleles of
the INSR gene have also been described harboring either
a heterozygous deletion or mutation of the HMGA1 gene,
but no mutations in the INSR gene (85). HMGA1 is an
architectural transcription factor that binds to key sites in
the promoter of the INSR gene to facilitate its transcription. Based on the single report to date, these patients
appeared to share many characteristics of patients with
INSR defects, consistent with the notion that a key function for HMGA1 is the stimulation of INSR expression.
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
edrv.endojournals.org
505
BSCL2a
CAV1a
PTRFa
Familial partial lipodystrophy
LMNAa
PPARGa
ZMPSTE24a
AKT2a
CIDECa
Acquired generalized
lipodystrophy
Associated with other
autoimmune diseases;
commonly also
associated with low C4
complement levels
Acquired partial lipodystrophy
HIV-associated
lipodystrophy
C3 nephritic factor
associated
AR
AR
AR (single case)
AR
AD
AD
AR
AD (single family)
AR (single case)
N/A
N/A
N/A
Ref.
15
67, 174
174
102
103106
15, 175
18, 176, 177179
19
107
14, 15
11, 13, 14
14
180
14
AD, Autosomal dominant; CGL, congenital generalized lipodystrophy; C3/4, complement factor 3/4; T2DM, type 2 diabetes mellitus; PCOS, polycystic ovary syndrome;
MPGN, mesangioproliferative glomerulonephritis; N/A, not applicable; SLE, systemic lupus erythematosus.
a
Genetic subtype.
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
506
Semple et al.
XI. Digenic IR
In 2002 (121), we described a family in which five severely
insulin-resistant subjects and no unaffected relatives
were doubly heterozygous for frameshift/premature stop
mutations in two unlinked genes, namely PPARG, a key
regulator of adipocyte biology, and PPP1R3A, a musclespecific protein involved in regulating glycogen turnover
(122125). This report was of particular interest because
the observation that genetic defects in molecules primarily
involved in either lipid or carbohydrate metabolism can
combine to result in an extreme phenotype of IR provides
a model for the type of metabolic interaction that may
underlie common forms of IR/type 2 diabetes.
Gene(s)
Alstrm
MOPDII
ALMS1
PCNT
Bardet Biedl
Bloom
Werner
Mandibuloacral
dysplasia
Myotonic
dystrophy
ZMPSTE24
DMPK
Adipose tissue
phenotype
IR disproportionate
to adiposity?
Cellular component or
function affected
Centripetal obesity
Centripetal fat
distribution
Obesity
Yes (127)
Yes (128)
Unclear (129)
Lipodystrophy
Lipodystrophy
Yes (133)
Yes (131132)
DNA repair
DNA repair
Lipodystrophy
None
Yes (181)
Transcriptional/splicing regulation
on chromosome 19, including
the INSR (182)
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
XIII. Therapy
The rarity and underdiagnosis of severe IR means that
almost all therapeutic decisions are based on rational targeting of underlying defects and anecdotal evidence rather
than randomized controlled trials. Therapy aims to reduce
hyperglycemia, to ameliorate dyslipidemia, and to lessen
the sometimes debilitating reproductive and cosmetic consequences of hyperinsulinemia. This is achieved first
through mitigation of the underlying signaling defect,
through minimizing secretory demands on the pancreatic
-cells, and through optimal delivery of exogenous insulin
when required. In the context of adipose tissue absence or
dysfunction, offloading adipose tissue by reducing lipid
delivery to it is also critical, and, finally, countering hyperandrogenism, ovulatory dysfunction, and acanthosis
nigricans by measures targeted at the relevant end organs
is also often of value. The treatment of such secondary
manifestations of the IR state has been reviewed elsewhere
(137, 138).
A. Dietary and lifestyle modification
In severe IR, whether or not a single gene defect is identified, weight gain inevitably exacerbates metabolic derangement and either worsens hyperglycemia in patients
with overt diabetes or increases -cell stress, so restricting
energy intake and maximizing aerobic exercise are essential elements of management. This is particularly important in lipodystrophy where the apparent leanness of patients frequently results in a failure of caregivers to place
sufficient emphasis on dietary modification. Indeed, failure to restrict energy intake in patients with lipodystrophy
makes it almost impossible to obtain good glycemic and
lipidemic control.
B. Insulin sensitization and replacement
Insulin-sensitizing agents also play a key role in management. Metformin is often effective, and in some cases
thiazolidinediones also exert markedly beneficial effects,
but no comparative studies exist to guide the choice of
therapy in different subgroups of severe IR. When -cell
decompensation occurs in severe IR to produce diabetes,
this is only relative to the very high insulin requirements,
and plasma insulin levels remain extremely elevated. This
means that insulin secretagogues such as sulfonylureas often produce little benefit. When insulin is required, this
may need to be used in concentrated form to achieve metabolic control (139), and limited evidence suggests that
delivery by sc infusion may be efficacious (140). Use of
recombinant human IGF-I has been reported mostly in the
setting of severe insulin receptoropathies and appears to
improve glycemia and perhaps survival in some infantile
cases (141151). It may exert activity by acting as an in-
edrv.endojournals.org
507
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
508
Semple et al.
XIV. Summary
Genetic syndromes of severe IR, with or without lipodystrophy, are underrecognized conditions that exact an immense toll of early morbidity and mortality for those affected. Considerable progress over the past 20 yr in
identifying the molecular basis of these disorders now
presents the opportunity for trials or therapy targeted at
specific subgroups of these patients. It is anticipated that
this will not only improve clinical outcomes for these rare
patients but will also give insights into the pathophysiology and therapy of more prevalent forms of IR.
8.
9.
10.
11.
Acknowledgments
Address all correspondence and requests for reprints to: Dr. R. K. Semple
or Dr. D. B. Savage, Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrookes Hospital, Hills
Road, Cambridge CB2 0QQ, United Kingdom. E-mail: rks16@cam.
ac.uk or dbs23@medschl.cam.ac.uk.
This work was supported by research grants from the Wellcome
Trust (Intermediate Clinical Fellowship 080952/Z/06/Z, to R.K.S.; Programme Grant 078986/Z/06/Z, to S.O.), GlaxoSmithKline (to D.B.S.),
the UK National Institute for Health Research Cambridge Biomedical
Research Centre, and the UK Medical Research Council Centre for Obesity and Related Metabolic Disease.
Disclosure Summary: R.K.S., D.B.S., E.K.C., and P.G. have nothing
to disclose. S.O. acts as a consultant in drug discovery for GlaxoSmithKline, Pfizer, and OSI Pharmaceuticals, Inc.
12.
13.
14.
15.
References
1. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu
W, Howard BV 2003 Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 26:861 867
2. Hanson RL, Imperatore G, Bennett PH, Knowler WC 2002
Components of the metabolic syndrome and incidence
of type 2 diabetes. Diabetes 51:3120 3127
3. Dunaif A, Segal KR, Futterweit W, Dobrjansky A 1989
Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165
1174
4. Reaven GM 1988 Banting lecture 1988. Role of insulin
resistance in human disease. Diabetes 37:15951607
5. Souren NY, Paulussen AD, Loos RJ, Gielen M, Beunen G,
Fagard R, Derom C, Vlietinck R, Zeegers MP 2007 Anthropometry, carbohydrate and lipid metabolism in the
East Flanders Prospective Twin Survey: heritabilities. Diabetologia 50:21072116
6. Freeman MS, Mansfield MW, Barrett JH, Grant PJ 2002
Heritability of features of the insulin resistance syndrome
in a community-based study of healthy families. Diabet
Med 19:994 999
7. Mills GW, Avery PJ, McCarthy MI, Hattersley AT, Levy
JC, Hitman GA, Sampson M, Walker M 2004 Heritability
16.
17.
18.
19.
20.
estimates for -cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes. Diabetologia 47:732738
Falchi M, Wilson SG, Paximadas D, Swaminathan R, Spector TD 2008 Quantitative linkage analysis for pancreatic
B-cell function and insulin resistance in a large twin cohort.
Diabetes 57:1120 1124
Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin
MM, Roth J 1976 The syndromes of insulin resistance and
acanthosis nigricans. Insulin-receptor disorders in man.
N Engl J Med 294:739 745
Sissons JG, West RJ, Fallows J, Williams DG, Boucher BJ,
Amos N, Peters DK 1976 The complement abnormalities
of lipodystrophy. N Engl J Med 294:461 465
Savage DB, Semple RK, Clatworthy MR, Lyons PA, Morgan BP, Cochran EK, Gorden P, Raymond-Barker P, Murgatroyd PR, Adams C, Scobie I, Mufti GJ, Alexander GJ,
Thiru S, Murano I, Cinti S, Chaudhry AN, Smith KG,
ORahilly S 2009 Complement abnormalities in acquired
lipodystrophy revisited. J Clin Endocrinol Metab 94:
10 16
Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden
P 2002 Clinical course of the syndrome of autoantibodies
to the insulin receptor (type B insulin resistance): a 28-year
perspective. Medicine (Baltimore) 81:87100
Misra A, Garg A 2003 Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore)
82:129 146
Misra A, Peethambaram A, Garg A 2004 Clinical features
and metabolic and autoimmune derangements in acquired
partial lipodystrophy: report of 35 cases and review of the
literature. Medicine (Baltimore) 83:18 34
Garg A 2004 Acquired and inherited lipodystrophies.
N Engl J Med 350:1220 1234
Flier JS, Kahn CR, Roth J 1979 Receptors, antireceptor
antibodies and mechanisms of insulin resistance. N Engl
J Med 300:413 419
Hjlund K, Hansen T, Lajer M, Henriksen JE, Levin K,
Lindholm J, Pedersen O, Beck-Nielsen H 2004 A novel
syndrome of autosomal-dominant hyperinsulinemic hypoglycemia linked to a mutation in the human insulin receptor gene. Diabetes 53:15921598
Agostini M, Schoenmakers E, Mitchell C, Szatmari I, Savage D, Smith A, Rajanayagam O, Semple R, Luan J, Bath
L, Zalin A, Labib M, Kumar S, Simpson H, Blom D, Marais
D, Schwabe J, Barroso I, Trembath R, Wareham N, Nagy
L, Gurnell M, ORahilly S, Chatterjee K 2006 Non-DNA
binding, dominant-negative, human PPAR mutations
cause lipodystrophic insulin resistance. Cell Metab 4:303
311
George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S,
Wilson JC, Soos MA, Murgatroyd PR, Williams RM,
Acerini CL, Dunger DB, Barford D, Umpleby AM, Wareham NJ, Davies HA, Schafer AJ, Stoffel M, ORahilly S,
Barroso I 2004 A family with severe insulin resistance and
diabetes due to a mutation in AKT2. Science 304:1325
1328
Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S,
Yki-Jarvinen H 2008 Increased liver fat, impaired insulin
clearance, and hepatic and adipose tissue insulin resistance
in type 2 diabetes. Gastroenterology 135:122130
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
edrv.endojournals.org
509
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
510
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
Semple et al.
blasts from patients with severe insulin resistance and pseudoacromegaly. A disorder characterized by selective
postreceptor insulin resistance. J Clin Invest 101:1111
1120
Kumar S, Durrington PN, ORahilly S, Laing I, Humphreys
PJ, Olukoga AO, Bhatnagar D, Mackness MI, Davis JR,
Boulton AJ 1996 Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudoacromegaly. J Clin
Endocrinol Metab 81:34653468
Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R 1999 Insulin
receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.
Mol Cell Biol 19:3278 3288
Pollak M 2008 Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915928
Rajaram S, Baylink DJ, Mohan S 1997 Insulin-like growth
factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18:801 831
Tsugane S, Inoue M 2010 Insulin resistance and cancer:
epidemiological evidence. Cancer Sci 101:10731079
Kang HW, Kim D, Kim HJ, Kim CH, Kim YS, Park MJ,
Kim JS, Cho SH, Sung MW, Jung HC, Lee HS, Song IS 2010
Visceral obesity and insulin resistance as risk factors for
colorectal adenoma: a cross-sectional, case-control study.
Am J Gastroenterol 105:178 187
Garg A 2000 Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy
(Dunnigan variety). J Clin Endocrinol Metab 85:1776
1782
Vantyghem MC, Vincent-Desplanques D, Defrance-Faivre
F, Capeau J, Fermon C, Valat AS, Lascols O, Hecart AC,
Pigny P, Delemer B, Vigouroux C, Wemeau JL 2008 Fertility and obstetrical complications in women with LMNArelated familial partial lipodystrophy. J Clin Endocrinol
Metab 93:22232229
Li S, Brown MS, Goldstein JL 2010 Bifurcation of insulin
signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA 107:34413446
Laplante M, Sabatini DM 2010 mTORC1 activates
SREBP-1c and uncouples lipogenesis from gluconeogenesis. Proc Natl Acad Sci USA 107:32813282
Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza
AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander
Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy
LO, Manning BD 2010 Activation of a metabolic gene
regulatory network downstream of mTOR complex 1.
Mol Cell 39:171183
Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J,
Boldt MD, Parks EJ 2005 Sources of fatty acids stored in
liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115:13431351
Haas JT, Biddinger SB 2009 Dissecting the role of insulin
resistance in the metabolic syndrome. Curr Opin Lipidol
20:206 210
Dann SG, Selvaraj A, Thomas G 2007 mTOR Complex
1-S6K1 signaling: at the crossroads of obesity, diabetes and
cancer. Trends Mol Med 13:252259
Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD,
Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA,
Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy Jr WS,
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
edrv.endojournals.org
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
511
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
512
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
Semple et al.
noya K, Sugano H, Nishino I 2009 Human PTRF mutations cause secondary deficiency of caveolins resulting in
muscular dystrophy with generalized lipodystrophy. J Clin
Invest 119:26232633
Rajab A, Straub V, McCann LJ, Seelow D, Varon R, Barresi R, Schulze A, Lucke B, Lutzkendorf S, Karbasiyan M,
Bachmann S, Spuler S, Schuelke M 2010 Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling
(CGL4) due to PTRF-CAVIN mutations. PLoS Genet
6:e1000874
Shastry S, Delgado MR, Dirik E, Turkmen M, Agarwal
AK, Garg A 2010 Congenital generalized lipodystrophy,
type 4 (CGL4) associated with myopathy due to novel
PTRF mutations. Am J Med Genet A 152A:22452253
Dwianingsih EK, Takeshima Y, Itoh K, Yamauchi Y,
Awano H, Malueka RG, Nishida A, Ota M, Yagi M, Matsuo M 2010 A Japanese child with asymptomatic elevation
of serum creatine kinase shows PTRF-CAVIN mutation
matching with congenital generalized lipodystrophy type
4. Mol Genet Metab 101:233237
Rubio-Cabezas O, Puri V, Murano I, Saudek V, Semple
RK, Dash S, Hyden CS, Bottomley W, Vigouroux C,
Magre J, Raymond-Barker P, Murgatroyd PR, Chawla A,
Skepper JN, Chatterjee VK, Suliman S, Patch AM, Agarwal
AK, Garg A, Barroso I, Cinti S, Czech MP, Argente J,
ORahilly S, Savage DB 2009 Partial lipodystrophy and
insulin resistant diabetes in a patient with a homozygous
nonsense mutation in CIDEC. EMBO Mol Med 1:280
287
Cohen AW, Hnasko R, Schubert W, Lisanti MP 2004 Role
of caveolae and caveolins in health and disease. Physiol Rev
84:13411379
Blouin CM, Le Lay S, Eberl A, Kofeler HC, Guerrera IC,
Klein C, Le Liepvre X, Lasnier F, Bourron O, Gautier JF,
Ferre P, Hajduch E, Dugail I 2010 Lipid droplet analysis in
caveolin-deficient adipocytes: Alterations in surface phospholipid composition and maturation defects. J Lipid Res
51:945956
Liu L, Brown D, McKee M, Lebrasseur NK, Yang D, Albrecht KH, Ravid K, Pilch PF 2008 Deletion of Cavin/
PTRF causes global loss of caveolae, dyslipidemia, and
glucose intolerance. Cell Metab 8:310 317
de Haan W 2010 Lipodystrophy and muscular dystrophy
caused by PTRF mutations. Clin Genet 77:436 437
Minetti C, Sotgia F, Bruno C, Scartezzini P, Broda P, Bado
M, Masetti E, Mazzocco M, Egeo A, Donati MA, Volonte
D, Galbiati F, Cordone G, Bricarelli FD, Lisanti MP, Zara
F 1998 Mutations in the caveolin-3 gene cause autosomal
dominant limb-girdle muscular dystrophy. Nat Genet 18:
365368
Keller P, Petrie JT, De Rose P, Gerin I, Wright WS, Chiang
SH, Nielsen AR, Fischer CP, Pedersen BK, MacDougald
OA 2008 Fat-specific protein 27 regulates storage of triacylglycerol. J Biol Chem 283:1435514365
Toh SY, Gong J, Du G, Li JZ, Yang S, Ye J, Yao H, Zhang
Y, Xue B, Li Q, Yang H, Wen Z, Li P 2008 Up-regulation
of mitochondrial activity and acquirement of brown adipose tissue-like property in the white adipose tissue of
fsp27 deficient mice. PLoS One 3:e2890
Nishino N, Tamori Y, Tateya S, Kawaguchi T, Shibakusa
T, Mizunoya W, Inoue K, Kitazawa R, Kitazawa S, Mat-
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB,
ORahilly S 1997 Congenital leptin deficiency is associated
with severe early-onset obesity in humans. Nature 387:
903908
Minton JA, Owen KR, Ricketts CJ, Crabtree N, Shaikh G,
Ehtisham S, Porter JR, Carey C, Hodge D, Paisey R,
Walker M, Barrett TG 2006 Syndromic obesity and diabetes: changes in body composition with age and mutation
analysis of ALMS1 in 12 United Kingdom kindreds with
Alstrom syndrome. J Clin Endocrinol Metab 91:3110
3116
Huang-Doran I, Bicknell LS, Finucane FM, Rocha N, Porter KM, Tung YC, Szekeres F, Krook A, Nolan JJ,
ODriscoll M, Bober M, ORahilly S, Jackson AP, Semple
RK 2011 Genetic defects in human pericentrin are associated with severe insulin resistance and diabetes mellitus.
Diabetes 60:925935
Green JS, Parfrey PS, Harnett JD, Farid NR, Cramer BC,
Johnson G, Heath O, McManamon PJ, OLeary E, PrysePhillips W 1989 The cardinal manifestations of BardetBiedl syndrome, a form of Laurence-Moon-Biedl syndrome. N Engl J Med 321:10021009
Zaghloul NA, Katsanis N 2009 Mechanistic insights into
Bardet-Biedl syndrome, a model ciliopathy. J Clin Invest
119:428 437
Yamada K, Ikegami H, Yoneda H, Miki T, Ogihara T
1999 All patients with Werners syndrome are insulin resistant, but only those who also have impaired insulin secretion develop overt diabetes. Diabetes Care 22:2094
2095
Imura H, Nakao Y, Kuzuya H, Okamoto M, Okamoto M,
Yamada K 1985 Clinical, endocrine and metabolic aspects
of the Werner syndrome compared with those of normal
aging. Adv Exp Med Biol 190:171185
Diaz A, Vogiatzi MG, Sanz MM, German J 2006 Evaluation of short stature, carbohydrate metabolism and other
endocrinopathies in Blooms syndrome. Horm Res 66:
111117
Jacob KN, Garg A 2006 Laminopathies: multisystem dystrophy syndromes. Mol Genet Metab 87:289 302
Schalch DS, McFarlin DE, Barlow MH 1970 An unusual
form of diabetes mellitus in ataxia telangiectasia. N Engl
J Med 282:1396 1402
Blevins Jr LS, Gebhart SS 1996 Insulin-resistant diabetes
mellitus in a black woman with ataxia-telangiectasia.
South Med J 89:619 621
Koulouri O, Conway GS 2009 Management of hirsutism.
BMJ 338:b847
Higgins SP, Freemark M, Prose NS 2008 Acanthosis nigricans: a practical approach to evaluation and management. Dermatol Online J 14:2
Cochran E, Musso C, Gorden P 2005 The use of U-500 in
patients with extreme insulin resistance. Diabetes Care 28:
1240 1244
Lane WS 2006 Use of U-500 regular insulin by continuous
subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance. Endocr Pract 12:251
256
Takahashi Y, Kadowaki H, Momomura K, Fukushima Y,
Orban T, Okai T, Taketani Y, Akanuma Y, Yazaki Y,
Kadowaki T 1997 A homozygous kinase-defective muta-
edrv.endojournals.org
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
513
tion in the insulin receptor gene in a patient with leprechaunism. Diabetologia 40:412 420
Nakae J, Kato M, Murashita M, Shinohara N, Tajima T,
Fujieda K 1998 Long-term effect of recombinant human
insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism. J Clin Endocrinol
Metab 83:542549
Longo N, Singh R, Griffin LD, Langley SD, Parks JS, Elsas
LJ 1994 Impaired growth in Rabson-Mendenhall syndrome: lack of effect of growth hormone and insulin-like
growth factor-I. J Clin Endocrinol Metab 79:799 805
Vestergaard H, Rossen M, Urhammer SA, Muller J, Pedersen O 1997 Short- and long-term metabolic effects of
recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus. Eur J Endocrinol 136:475 482
Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, Suzuki Y, Kobayashi M, Akazawa
Y, Nomura M 1993 Trial of insulin-like growth factor I
therapy for patients with extreme insulin resistance syndromes. Diabetes 42:696 705
Zenobi PD, Glatz Y, Keller A, Graf S, Jaeggi-Groisman SE,
Riesen WF, Schoenle EJ, Froesch ER 1994 Beneficial metabolic effects of insulin-like growth factor I in patients with
severe insulin-resistant diabetes type A. Eur J Endocrinol
131:251257
Dozio N, Scavini M, Beretta A, Sartori S, Meschi F, Sarugeri E, Pozza G 1995 In vivo metabolic effects of insulinlike growth factor-I not mediated through the insulin receptor. J Clin Endocrinol Metab 80:13251328
Quin JD, Checkley A, Gallagher A, Jones J, MacCuish AC,
Miell JP 1994 Response of insulin-like growth factor
(IGF)-binding protein-1 (IGFBP-1) and IGFBP-3 to IGF-I
treatment in severe insulin resistance. J Endocrinol 141:
177182
George S, Johansen A, Soos MA, Mortensen H, Gammeltoft S, Saudek V, Siddle K, Hansen L, ORahilly S 2003
Deletion of V335 from the L2 domain of the insulin receptor results in a conformationally abnormal receptor
that is unable to bind insulin and causes Donohues syndrome in a human subject. Endocrinology 144:631 637
McDonald A, Williams RM, Regan FM, Semple RK,
Dunger DB 2007 IGF-I treatment of insulin resistance. Eur
J Endocrinol 157(Suppl 1):S51S56
Regan FM, Williams RM, McDonald A, Umpleby AM,
Acerini CL, ORahilly S, Hovorka R, Semple RK, Dunger
DB 2010 Treatment with recombinant human insulin-like
growth factor (rhIGF)-I/rhIGF binding protein-3 complex
improves metabolic control in subjects with severe insulin
resistance. J Clin Endocrinol Metab 95:21132122
Haque WA, Shimomura I, Matsuzawa Y, Garg A 2002
Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 87:2395
Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A,
Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI,
Gorden P, Garg A 2002 Leptin-replacement therapy for
lipodystrophy. N Engl J Med 346:570 578
Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu
C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman
GI 2002 Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest
109:13451350
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.
514
Semple et al.
155. Javor ED, Ghany MG, Cochran EK, Oral EA, DePaoli AM,
Premkumar A, Kleiner DE, Gorden P 2005 Leptin reverses
nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41:753760
156. Beltrand J, Beregszaszi M, Chevenne D, Sebag G, De Kerdanet M, Huet F, Polak M, Tubiana-Rufi N, Lacombe D,
De Paoli AM, Levy-Marchal C 2007 Metabolic correction
induced by leptin replacement treatment in young children
with Berardinelli-Seip congenital lipoatrophy. Pediatrics
120:e291 e296
157. Chong AY, Lupsa BC, Cochran EK, Gorden P 2010 Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 53:2735
158. Beltrand J, Lahlou N, Le Charpentier T, Sebag G, Leka S,
Polak M, Tubiana-Rufi N, Lacombe D, de Kerdanet M,
Huet F, Robert JJ, Chevenne D, Gressens P, Levy-Marchal
C 2010 Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological
origin. Eur J Endocrinol 162:10831091
159. Savage DB, ORahilly S 2010 Leptin therapy in lipodystrophy. Diabetologia 53:79
160. Mantzoros CS 2009 Whither recombinant human leptin
treatment for HIV-associated lipoatrophy and the metabolic syndrome? J Clin Endocrinol Metab 94:1089 1091
161. Cochran E, Young JR, Sebring N, DePaoli A, Oral EA,
Gorden P 2004 Efficacy of recombinant methionyl human
leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. J Clin Endocrinol Metab 89:
1548 1554
162. Skarulis MC, Celi FS, Mueller E, Zemskova M, Malek R,
Hugendubler L, Cochran C, Solomon J, Chen C, Gorden
P 2010 Thyroid hormone induced brown adipose tissue
and amelioration of diabetes in a patient with extreme insulin resistance. J Clin Endocrinol Metab 95:256 262
163. Moreira RO, Zagury RL, Nascimento TS, Zagury L 2010
Multidrug therapy in a patient with Rabson-Mendenhall
syndrome. Diabetologia 53:2454 2455
164. Utzschneider KM, Trence DL 2006 Effectiveness of gastric
bypass surgery in a patient with familial partial lipodystrophy. Diabetes Care 29:1380 1382
165. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson
C, Arioglu E, Gavrilova O, Reitman ML 2000 Adipose
tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 106:
12211228
166. Moreau F, Boullu-Sanchis S, Vigouroux C, Lucescu C, Lascols O, Sapin R, Ruimy D, Guerci B, Pinget M, Jeandidier
N 2007 Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report. Diabetes
Metab 33:385389
167. Simha V, Rao S, Garg A 2008 Prolonged thiazolidinedione
therapy does not reverse fat loss in patients with familial
partial lipodystrophy, Dunnigan variety. Diabetes Obes
Metab 10:12751276
168. Collet-Gaudillat C, Billon-Bancel A, Beressi JP 2009 Longterm improvement of metabolic control with pioglitazone
in a woman with diabetes mellitus related to Dunnigan
syndrome: a case report. Diabetes Metab 35:151154
169. Dash S, Langenberg C, Fawcett KA, Semple RK, Romeo S,
Sharp S, Sano H, Lienhard GE, Rochford JJ, Howlett T,
Massoud AF, Hindmarsh P, Howell SJ, Wilkinson RJ, Lys-
170.
171.
172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 25 September 2014. at 12:56 For personal use only. No other uses without permission. . All rights reserved.